Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1 1

Status

Active not recruiting 3Completed 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4

Conditions

Small Cell Lung Carcinoma 46Lymphoma, Large B-Cell, Diffuse 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia, Myeloid, Acute 20Lung Neoplasms 19Burkitt Lymphoma 18Recurrence 14Lymphoma 14Hodgkin Disease 14Lymphoma, Non-Hodgkin 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Neuroblastoma 10Lymphoma, Mantle-Cell 10Lymphoma, B-Cell 10Leukemia 10Carcinoma, Non-Small-Cell Lung 10Medulloblastoma 8Neoplasms, Germ Cell and Embryonal 7Neoplasms 7Lymphoma, Follicular 7Multiple Myeloma 6Lymphoma, T-Cell 6Brain Neoplasms 6Sarcoma, Ewing 5Retinoblastoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Immunoblastic Lymphadenopathy 5Ependymoma 5Rhabdomyosarcoma 4Rhabdoid Tumor 4

Interventions

pembrolizumab 119Cisplatin 33lenvatinib 29Carboplatin 28Paclitaxel 27Docetaxel 14Pemetrexed 13Fluorouracil 12Capecitabine 11Saline Solution 10Oxaliplatin 10Gemcitabine 10Albumin-Bound Paclitaxel 7olaparib 6Leucovorin 6Bevacizumab 6epacadostat 5belzutifan 5Etoposide 5Cetuximab 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 3regorafenib 3patritumab deruxtecan 3enzalutamide 3enfortumab vedotin 3durvalumab 3Surgical Procedures, Operative 3Radiotherapy 3Levoleucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Etoposide × 1 year × Clear all
NCT04624204 2026-05-26

MK 7339-013

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
672 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04380636 2026-05-15

MK-7339-012

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
870 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02964013 2025-10-14

KEYVIBE-001

Merck Sharp & Dohme LLC

Phase 1 Completed
474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT05298423 2025-08-01

KEYVIBE-006

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
611 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04924101 2025-07-23

KEYNOTE-B99

Merck Sharp & Dohme LLC

Phase 2 Completed
126 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡